0001209191-20-024991.txt : 20200417
0001209191-20-024991.hdr.sgml : 20200417
20200417200014
ACCESSION NUMBER: 0001209191-20-024991
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200415
FILED AS OF DATE: 20200417
DATE AS OF CHANGE: 20200417
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chereau Frederic
CENTRAL INDEX KEY: 0001640592
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38707
FILM NUMBER: 20801030
MAIL ADDRESS:
STREET 1: C/O ATYR PHARMA, INC.
STREET 2: 3545 JOHN HOPKINS COURT, SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664106
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 471514975
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 65 HAYDEN AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-245-0399
MAIL ADDRESS:
STREET 1: 65 HAYDEN AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-15
0
0001664106
LogicBio Therapeutics, Inc.
LOGC
0001640592
Chereau Frederic
65 HAYDEN AVENUE, FLOOR 2
LEXINGTON
MA
02421
1
1
0
0
President and Chief Executive
Restricted Stock Units
2020-04-15
4
A
0
23414
0.00
A
Common Stock
23414
23414
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of LogicBio Therapeutics Inc. (the "Company") common stock.
The RSUs will fully vest on April 15, 2021, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan; provided, that if the reporting person's employment is terminated by the Company without "cause" or by the reporting person for "good reason" (as defined in the reporting person's employment agreement) prior to April 15, 2021, all such RSUs will vest on the date of termination.
/s/ Matthias Jaffe, as Attorney-in-Fact
2020-04-17